Ultragenyx Pharmaceutical Inc at Citi BioPharma Conference Transcript
So welcome, everyone. I'm Yigal Nochomovitz, one of the biotech analysts at Citi. My pleasure to have with me my colleague, Samantha Semenkow, recently rejoined Citi as a senior analyst. This is the rare neuro panel, and it's my pleasure to have with me two distinguished CEOs in the space. Carole Ben-Maimon, the CEO of Lamar and Emil Kakkis, the CEO of Ultragenyx. So welcome, both of you. Thank you very much for taking the time. And maybe just to start out, if you could just give a very brief 2- or 3-minute overview of some of the rare neurology programs that you're focused on. And then from there, we can move into some more thematic questions related to development of drugs for rare neurology. So Emil, you want to start?
Okay. Sure. Good morning, everyone. So I'm Emil Kakkis, CEO of Ultragenyx. And we've been formed for about 13 years ago and have been building a portfolio of products in the [born] errors,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
